tipifarnib has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonginelli, P; Capaccetti, B; Fanelli, M; Gasparini, G; Gattuso, D; Longo, R; Sarmiento, R | 1 |
| Cohen-Jonathan, E; Delmas, C; End, D; Favre, G; Rochaix, P; Toulas, C | 1 |
1 review(s) available for tipifarnib and Angiogenesis, Pathologic
| Article | Year |
|---|---|
[Innovative treatment in oncology].
Topics: Antibodies, Monoclonal; Humans; Neoplasms; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinolones | 2002 |
1 other study(ies) available for tipifarnib and Angiogenesis, Pathologic
| Article | Year |
|---|---|
The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Cell Hypoxia; Enzyme Inhibitors; Farnesyltranstransferase; Glioblastoma; Glioma; Humans; Immunoenzyme Techniques; Matrix Metalloproteinase 2; Mice; Mice, Nude; Neovascularization, Pathologic; Oxygen; Quinolones; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |